We are live on ! Find out more
FBT icon

First Trust NYSE Arca Biotechnology Index Fund

219 hedge funds and large institutions have $666M invested in First Trust NYSE Arca Biotechnology Index Fund in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 95 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

2.19% less ownership

Funds ownership: 47.02%44.83% (-2.2%)

11% less funds holding

Funds holding: 246219 (-27)

17% less capital invested

Capital invested by funds: $803M → $666M (-$136M)

51% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 47

53% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 95

Holders
219
Holders Change
-27
Holders Change %
-10.98%
% of All Funds
3.44%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
45
Reduced
95
Closed
47
Calls
$1.16M
Puts
Net Calls
+$1.16M
Net Calls Change
+$1.21M

FBT Hedge Fund Activity: Q1 2022 in Review

219 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q1 2022, worth a combined $666M — down 17% from $803M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of FBT and 23 opened new positions — a net loss of 24 holders — while 95 trimmed existing stakes and 45 added.

The largest buyer was Old Mission Capital, opening a new position worth an estimated $4.33M. The largest seller was Morgan Stanley, cutting an estimated $15.3M.

  • 219 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q1 2022, down from 246 in Q4 2021.
  • Funds reported $666M of First Trust NYSE Arca Biotechnology Index Fund stock for Q1 2022, down 17% quarter-over-quarter.
  • 23 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q1 2022 and 47 closed out, a net change of -24 holders.
  • The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q1 2022 was Old Mission Capital, an estimated $4.33M added.
  • The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q1 2022 was Morgan Stanley, an estimated $15.3M sold.

Based on aggregated 13F filings for Q1 2022.